1145-15-9

Usage

Uses

Used in Organic Synthesis:
5-(3,4-dimethoxyphenyl)pentanoic acid is used as a building block in organic synthesis for the creation of various pharmaceutical and biologically active compounds, leveraging its unique structural features to enhance the properties of synthesized molecules.
Used in Pharmaceutical Research:
In Pharmaceutical Research, 5-(3,4-dimethoxyphenyl)pentanoic acid is used as a key intermediate for the development of new drugs, contributing to the advancement of medicinal chemistry through its potential to form novel therapeutic agents.
Used in Medicinal Chemistry Research:
5-(3,4-dimethoxyphenyl)pentanoic acid is used as a subject of study in medicinal chemistry research for its potential anti-inflammatory and analgesic properties, indicating its possible use in the treatment of inflammation and pain.
Used in the Development of Anti-inflammatory Agents:
In the field of anti-inflammatory drug development, 5-(3,4-dimethoxyphenyl)pentanoic acid is used as a precursor compound for the synthesis of agents that may help in reducing inflammation, offering a new avenue for the treatment of conditions characterized by inflammatory responses.
Used in the Development of Analgesic Agents:
Similarly, in the development of analgesic agents, 5-(3,4-dimethoxyphenyl)pentanoic acid is utilized for its potential to contribute to the creation of pain-relieving medications, providing an alternative or complementary approach to existing analgesics.

InChI:InChI=1/C13H18O4/c1-16-11-8-7-10(9-12(11)17-2)5-3-4-6-13(14)15/h7-9H,3-6H2,1-2H3,(H,14,15)

Upstream product

• 101619-71-0 (2E,4E)-ethyl 5-(3,4-dimethoxyphenyl)penta-2,4-dienoate 
• 874518-45-3 5-(3,4-dimethoxyphenyl)pentanoic acid ethyl ester 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 141-82-2 malonic acid 
• 61871-67-8 3-(3,4-Dimethoxyphenyl)propanal 
• 3929-47-3 3-(3,4-dimethoxyphenyl)-1-propanol 
• 5462-13-5 ethyl 3-(3,4-dimethoxyphenyl)propionate 
• 20583-78-2 3,4-dimethoxy-cinnamic acid ethyl ester 
• 2316-26-9 3,4-dimethoxycinnamic acid 
• 131699-18-8 methyl 5-(3,4-dimethoxyphenyl)pentanoate 
• 131699-22-4 5-(3,4-dimethoxy-phenyl)-5-oxo-pentanoic acid methyl ester 
• 855655-55-9 (3-(3,4-Dimethoxy-phenyl)-allyliden)-malonsaeure 
• 91-16-7 1,2-dimethoxybenzene 
• 108-55-4 glutaric anhydride, 

Downstream Products

• 31129-94-9 5-(3′,4′,5′-trihydroxyphenyl)valeric acid 
• 79623-17-9 1,2-dimethoxy-4-(5-hydroxypentyl)benzene 
• 1452406-10-8 6-(3,4-dimethoxyphenyl)-1,1,1-trifluorohexan-2-one 
• 1452406-19-7 7-(3,4-dimethoxyphenyl)-1,1,1,2,2-pentafluoroheptan-3-one 
• 392632-16-5 4-[4-(2-{[(2S)-3-(4-{[tert-Butyl(diphenyl)silyl]oxy}phenoxy)-2-hydroxypropyl]amino}ethyl)anilino]-N-[4-(3,4-dimethoxyphenyl)butyl]-1-piperidinecarboxamide 
• 392631-88-8 4-(4-{2-[2-Hydroxy-3-(4-hydroxy-phenoxy)-propylamino]-ethyl}-phenylamino)-piperidine-1-carboxylic acid [4-(3,4-dimethoxy-phenyl)-butyl]-amide 
• 1609188-58-0 2,3-dimethoxy-5-(2-methoxyphenyl)-8,9-dihydro-7H-benzocycloheptene-6-carboxylic acid 
• 1609188-55-7 2,3-dimethoxy-5-(2-methoxyphenyl)-8,9-dihydro-7H-benzocycloheptene-6-carbaldehyde 
• 91869-10-2 1-<5-<3,4-Bis(trimethylsilyloxy)phenyl>-1-oxopentyl>-4-trimethylsilyloxypiperidin 
• 91887-07-9 1-<5-(3,4-Dimethoxyphenyl)-1-oxopentyl>-4-hydroxypiperidin 
• 91869-11-3 5-(3,4-Dihydroxy-phenyl)-1-(4-hydroxy-piperidin-1-yl)-pentan-1-one 
• 91887-06-8 1-<5-(3,4-Dimethoxyphenyl)-1-oxopentyl>piperidin 
• 220396-72-5 2-(4-ethoxycarbonylbutyl)-4,5-dimethoxybenzenesulfonamide 
• 220396-70-3 2-(4-ethoxycarbonylbutyl)-4,5-dimethoxybenzenesulfonyl chloride 

Relevant academic research and scientific papers

In silico design and synthesis of N-arylalkanyl 2-naphthamides as a new class of non-purine xanthine oxidase inhibitors

A series of N-arylalkanyl 2-naphthamides (Xa~e), which were predicted from virtual molecular docking on a built xanthine oxidase template as potential inhibitors, were synthesized. Their inhibitory activity against xanthine oxidase was assayed. Among these prepared, compounds Xb (IC50 13.6?μM), Xc (IC50 13.1?μM), and Xd (IC50 12.5?μM) showed comparable inhibitory activity to allopurinol (IC50 22.1?μM). The in vitro assay result correlated well with molecular docking scores, ΔG?=??16.99, ?17.66, and ?17.13 Kcal/mol, respectively. On the potassium oxonate-induced hyperuricemic mice model, oral administration of Xc-Ac (40 mg/ Kg), the per-O-acetylated Xc, could reduce the blood uric acid level by 60% in comparison to the normal control group and is statistically significant (p .01) while compared with the hyperuricemic mice group.

Synthesis of Medium-Ring-Sized Benzolactams by Using Strong Electrophiles and Quantitative Evaluation of Ring-Size Dependency of the Cyclization Reaction Rate

Benzolactams with medium-sized rings were synthesized via the electrophilic aromatic substitution reaction of carbamoyl cations (R1R2N+═C═O) in good to high yields without dilution. These reactions were utilized to quantitatively examine the extent of retardation of medium-sized ring formation, compared to five- or six-membered ring formation. The order of reaction rates of formation of cyclic benzolactams is six- > five- > seven- > eight- > nine-membered ring at 25 °C. The present reaction provides a route to eight- A nd nine-membered benzolactams.

Iridium/f-Amphol-catalyzed Efficient Asymmetric Hydrogenation of Benzo-fused Cyclic Ketones

Iridium/f-Amphol-catalyzed asymmetric hydrogenation of various benzo-fused five to seven-membered cyclic ketones was successfully developed, affording a series of chiral benzo-fused cyclic alcohols with excellent results (75%–99% yields, 93%–>99% ee, and TON up to 297 000). The enantioenriched products can be employed as key intermediates or motifs for the synthesis of some important biologically active compounds, such as rasagiline mesylate TVP-1012 used for the treatment of Parkinson's disease, the enantiomer of anticonvulsant drug eslicarbazepine acetate (BIA 2-093). (Figure presented.).

Intramolecular Friedel-Crafts Acylation Reaction Promoted by 1,1,1,3,3,3-Hexafluoro-2-propanol

Simple dissolution of an arylalkyl acid chloride in 1,1,1,3,3,3-hexafluoro-2-propanol promotes an intramolecular Friedel-Crafts acylation without additional catalysts or reagents. This reaction is operationally trivial in both execution and product isolation (only requiring concentration followed by purification) and accommodates a broad range of substrates. Preliminary studies that bear upon potential reaction mechanisms are reported.

Synthesis of novel building blocks of benzosuberone bearing coumarin moieties and their evaluation as potential anticancer agents

A series of novel benzosuberone bearing coumarin moieties 5a-c have been synthesized and their structures were determined by analytical and spectral (FT-IR, 1H NMR, 13C NMR, HRMS) studies. The newly synthesized compounds were evaluated for their cytotoxicity against four human cancer cell lines, A549 (Human alveolar adenocarcinoma cell line), HeLa (Human cervical cancer cell line), MDA-MB-231 (Human breast adenocarcinoma cell line), MCF-7 (Human breast adenocarcinoma cell line) and normal cell line HEK293 (Human embryonic kidney cell line). Compound 5a exhibited promising cytotoxicity with IC50 values ranging from 3.35 to 16.79 μM against all the cancer cell lines like A549, HeLa, MCF-7 and MDA-MB-231, while compound 5c showed significant cytotoxicity against HeLa and MDA-MB-231 with IC50 values of 6.72 and 4.87, respectively.

New potent and selective polyfluoroalkyl ketone inhibitors of GVIA calcium-independent phospholipase A2

Group VIA calcium-independent phospholipase A2 (GVIA iPLA 2) has recently emerged as an important pharmaceutical target. Selective and potent GVIA iPLA2 inhibitors can be used to study its role in various neurological diso

Ring enlargement of eight- and nine-membered cyclic sulfonamide derivatives in reactions with 3-amino-2H-azirines

The reactions of 3-dimethylamino-2H-azirines (1) with 3,4,5,6- tetrahydro-8,9-dimethoxy-2H-1,2-benzothiazocin-3-one 1,1-dioxide (6a) in acetonitrile gave the correspondingly substituted 3-dimethylamino- 4,5,6,7,8,9-hexahydrobenzo-1-thia-2,5-diazacyclounde

Synthesis and in vitro antibacterial activities of novel conformationally restricted hygromycin A analogues

The preparation of semisynthetic conformationally restricted hygromycin A analogues are described. Antibacterial results from these compounds suggest active conformations for this class of agents.

PHARMACOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME

Pharmacologically active catechol derivatives of formula I I wherein R1 and R2 independently comprise hydrogen, alkyl, acyl, optionally substituted aroyl, lower alkylsulfonyl or alkylcabamoyl or taken together form a lower alkylidene or cycloalkylidene, X comprises an electronegative substituent such as halogen, nitro, cyano, lower alkylsulfonyl, sulfonamido, aldehyde, caboxyl or trifluoromethyl and R3 comprises hydrogen, halogen, hydroxy alkyl, amino, nitro, cyano, trifluoromethyl, lower alkylsulfonyl, sulfonamide, aldehyde, alkyl carbonyl, aralkylidene carbonyl or carboxyl or a group selected from wherein R4 comprises hydrogen, alkyl, cyano, carboxyl or acyl and R5 comprises hydrogen, cyano, carboxyl, alkoxycarbonyl, carboxyalkenyl, nitro, acyl, optionally substituted aroyl or heteroaroyl, hydroxyalkyl or carboxyalkyl or R4 and R5 together form a five to seven membered substituted cycloalkanone ring; -(CO)n(CH2)m-COR wherein n is 0-1 and m is 0-7 and R comprises hydroxy, alkyl, carboxyalkyl, optionally substituted alkene, alkoxy or optionally substituted amino; wherein R8 and R9 independently comprise hydrogen or one of the following optionally substituted groups; alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, or together form an optionally substituted piperidyl group; -NH-CO-R10 wherein R10 comprises a substituted alkyl group